Immunome Inc.

IMNM | NASDAQ

Price Alert Chart Builder DCF Calculator

$25.75

+$0.68 (+2.71%)

Sep 22, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

No market cap data available

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Market Cap
ABCL AbCellera Biologics	3.87B
BHVN Biohaven	2.14B
CLDX Celldex Therapeutics	2.52B
MAZE Maze Therapeutics	1.24B
NTLA Intellia Therapeutics	1.71B
PHVS Pharvaris	2.52B
SYRE Spyre Therapeutics	7.99B
UPB Upstream Bio	291.96M
VERA Vera Therapeutics	2.46B
ZBIO Zenas BioPharma	2.05B

Recent News

16 days ago / businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 days ago / businesswire.com
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
1 month ago / marketbeat.com
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
1 month ago / globenewswire.com
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
1 month ago / seekingalpha.com
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
2 months ago / businesswire.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
2 months ago / fool.com
What This Immunome Sale Means a Day Before a Big FDA Milestone
3 months ago / zacks.com
Immunome Stock Up 32% in a Month: Here's What You Should Know
3 months ago / businesswire.com
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
4 months ago / gurufocus.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors